Chardan Analysts Initiates Coverage On Akari Therapeutics With A Sell Rating
July 11, 2016 at 09:00 AM EDT
Although there are catalysts for Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) in 2H16, the inferior dosing schedule for coversin and ...